The EMA’s pharmacovigilance risk assessment committee(PRAC) recommended the revocation of the EU authorization of medicines containing pholcodine, a morphinan alkaloid derivative of morphine used as an antitussive medication to treat non-productive dry cough in adults and children. The data showed that pholcodine increased the risk of life-threatening anaphylactic reactions to neuromuscular blocking agents used in general anesthesia (NMBAs).
References https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-pholcodine-medicines-eu-market
Comments
Post a Comment